Type1 diabetes usually develops in children or young adults and requires daily insulin to survive. Scientist report that patients with Type 1 diabetes who become infected with the COVID19 may develop a diabetes complication known as ketoacidosis.
A study in 180 patients from across the United States with type 1 diabetes and COVID-19 included 43% White, 31% Black and 26% Hispanic subjects.
The Journal of Clinical Endocrinology and Metabolism paper reported that Black and Hispanic subjects had an increased risk of developing a complication of type 1 diabetes called diabetic ketoacidosis (DKA).
This increased risk in Blacks and Hispanics type1 diabetes patients appears to be linked to a significantly worse blood sugar control in these patient groups. The reason of this complication’s risk could be due to a less frequent use of new diabetes technology like continuous glucose monitoring and insulin pumps (https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgaa920/6042218).
Specializing in rare disease, Boston Biotech Clinical Research works with biotech, pharmaceutical, device companies and investors to streamline the clinical trial process. Our experienced team helps each client reach their specific goals by customizing a clinical and regulatory road map of simplified programs and streamlined protocols to meet our clients’ requirements.